Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

CAPS Rating: 1 out of 5

Results 1 - 12 of 12

Recs

0
Member Avatar pchop12316 (86.75) Submitted: 8/18/2014 1:44:56 PM : Outperform Start Price: $287.45 ICPT Score: -1.97

horse to be ridden

Recs

0
Member Avatar manirg (66.40) Submitted: 8/14/2014 9:49:31 AM : Outperform Start Price: $294.89 ICPT Score: -5.47

2-3x potential

Recs

0
Member Avatar pchop123 (79.60) Submitted: 8/7/2014 11:33:45 AM : Outperform Start Price: $225.29 ICPT Score: +22.40

jump back on this one for a good UP !!!

Recs

0
Member Avatar Flygal5 (99.15) Submitted: 3/17/2014 3:16:09 PM : Outperform Start Price: $402.99 ICPT Score: -36.15

Took a breather, now I am ready to be back in.

Recs

0
Member Avatar naughtyguy (30.67) Submitted: 3/13/2014 10:46:34 AM : Underperform Start Price: $455.00 ICPT Score: +43.87

Market cap over $8 billion?

Recs

2
Member Avatar NewbiesRock (< 20) Submitted: 2/18/2014 5:40:46 AM : Underperform Start Price: $353.89 ICPT Score: +27.72

I picked underperformed because the Intercept Molecule had some negative impact on cholesterol and it seems they didn't fix that problem yet. The FDA will probably want to look deeper into that. Furthermore another company that has a very good molecule is its French competitor: Genfit. It has a molecule that has impressive results so far and a great potential in other fields (so will be able to get multiple revenue stream in the future). The GFT505 (the molecule Genfit is working on) recently got a fast track status from the FDA. I'd be careful of Intercept.

Recs

0
Member Avatar genedom (97.50) Submitted: 2/11/2014 2:27:10 AM : Outperform Start Price: $374.01 ICPT Score: -34.46

A highly likely buyout target.

Recs

2
Member Avatar zzlangerhans (99.77) Submitted: 1/29/2014 8:10:48 AM : Outperform Start Price: $307.32 ICPT Score: -18.71

Last year I red thumbed Intercept at around 37 based on the too much, too soon concept that the share price had gotten ahead of prospects. That hasn't been a very good strategy for me. I should probably confine myself to red thumbing spikes on BS press releases from companies I know are going to fail eventually. In this case I'm getting behind Intercept not because I buy this whole NASH hysteria, but because OCA is being developed for numerous hepatic indications besides NASH and data will be reported for several of those indications in coming months. Data from the POISE trial in primary biliary sclerosis will be reported next quarter. Encouraging preliminary data from PESTO (portal hypertension) and OBADIAH (bile acid diarrhea) has already been released and more complete data sets will be presented at conferences in April and May respectively.

Intercept's share price has receded considerably from the giddy highs in the upper 400's after the FLINT trial was unexpectedly terminated for efficacy at an interim analysis but could certainly revisit those levels and higher if OCA proves as active in other indications as it did for NASH. The zzporte portfolio has 30 shares with a cost basis of 311.

Recs

0
Member Avatar sinvestor (40.64) Submitted: 1/14/2014 6:38:16 AM : Underperform Start Price: $361.00 ICPT Score: +30.43

Looks like a joke to me...

Recs

1
Member Avatar Emjae06 (< 20) Submitted: 1/11/2014 6:45:48 PM : Outperform Start Price: $339.87 ICPT Score: -24.69

Maybe it would continue to go up.

Recs

0
Member Avatar tad40 (99.69) Submitted: 1/11/2014 10:46:58 AM : Underperform Start Price: $339.87 ICPT Score: +24.69

what goes up must come down. lol

Recs

0
Member Avatar IBDContrarian (21.65) Submitted: 12/18/2012 10:51:29 AM : Underperform Start Price: $34.40 ICPT Score: -688.39

IBD EPS, RS, SPROE, Acc ratings plus P/E and div yield
MEDICAL 4 99 DA, NO EARNINGS

Results 1 - 12 of 12

Featured Broker Partners


Advertisement